Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-naïve
Chinese HIV-infected patients.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
CAMS Initiative for Innovative Medicine National Key Technologies R&D Program for the 12th Five-year Plan National Key Technologies R&D Program for the 13th Five-year Plan